|
|
Blood, 15 April 2004, Vol. 103, No. 8, pp. 2873-2878.
Prepublished online as a Blood First Edition Paper on December 24, 2003; DOI 10.1182/blood-2003-11-3800.
 Previous Article | Table of Contents | Next Article 
PLENARY PAPERS
High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome–positive chronic phase chronic myeloid leukemia
Hagop Kantarjian,
Moshe Talpaz,
Susan O'Brien,
Guillermo Garcia-Manero,
Srdan Verstovsek,
Francis Giles,
Mary Beth Rios,
Jianqin Shan,
Laurie Letvak,
Deborah Thomas,
Stefan Faderl,
Alessandra Ferrajoli, and
Jorge Cortes
From the Departments of Leukemia and Bioimmunotherapy, The University of Texas, M. D. Anderson Cancer Center, Houston, TX; and Novartis Pharmaceuticals, East Hanover, NJ.
Imatinib mesylate (STI571) is effective in chronic phase chronic myelogenous leukemia (CML). However, most patients treated with 400 mg imatinib daily have variable levels of residual molecular disease. We treated 114 patients with newly diagnosed chronic phase CML with 400 mg imatinib twice daily. Overall, 109 patients (96%) had a major cytogenetic response (Philadelphia chromosome [Ph] < 35%), and 103 (90%) had a complete response (Ph 0%). With a median follow-up of 15 months, no patient has progressed to accelerated or blastic phase. The estimated 2-year survival rate was 94%. By quantitative polymerase chain reaction (QPCR) studies, 71 (63%) of 112 patients showed BCR-ABL/ABL percentage ratios decrease to less than 0.05%, and 31 (28%) to undetectable levels. Compared with standard-dose imatinib, high-dose imatinib was associated with significantly better complete cytogenetic response (P = .0005), major molecular response (QPRC < 0.05%; P = .00001), and complete molecular response (undetectable BCR-ABL; P = .001). High-dose imatinib was well tolerated but resulted in more frequent myelosuppression; 82% of patients continue to receive 600 mg or more of imatinib daily. In conclusion, high-dose imatinib induced higher rates of complete cytogenetic response and of molecular response in patients with newly diagnosed chronic phase CML. (Blood. 2004; 103:2873-2878)
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
Related Article in Blood Online:
-
Can we cure CML?
- Brian J. Druker
Blood 2004 103: 2865-2866.
[Full Text]
[PDF]
Related Letter in Blood Online:
-
Discontinuation of imatinib therapy after achieving a molecular response
- Jorge Cortes, Susan O'Brien, and Hagop Kantarjian
Blood 2004 104: 2204-2205.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
J. E. Cortes
Imatinib Therapy for Chronic Myeloid Leukemia: Where Do We Go Now?
J. Clin. Oncol.,
July 10, 2008;
26(20):
3308 - 3309.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Palandri, I. Iacobucci, F. Castagnetti, N. Testoni, A. Poerio, M. Amabile, M. Breccia, T. Intermesoli, F. Iuliano, G. Rege-Cambrin, et al.
Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon-{alpha}: 5-year outcome
Haematologica,
May 1, 2008;
93(5):
770 - 774.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Deenik, B. van der Holt, G. E. G. Verhoef, W. M. Smit, M. J. Kersten, H. C. Kluin-Nelemans, L. F. Verdonck, A. Ferrant, A. V. M. B. Schattenberg, J. J. W. M. Janssen, et al.
Dose-finding study of imatinib in combination with intravenous cytarabine: feasibility in newly diagnosed patients with chronic myeloid leukemia
Blood,
March 1, 2008;
111(5):
2581 - 2588.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, F. Pane, and G. Saglio
Monitoring treatment of chronic myeloid leukemia
Haematologica,
February 1, 2008;
93(2):
161 - 169.
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Hochhaus, B. Druker, C. Sawyers, F. Guilhot, C. A. Schiffer, J. Cortes, D. W. Niederwieser, C. Gambacorti-Passerini, R. M. Stone, J. Goldman, et al.
Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-{alpha} treatment
Blood,
February 1, 2008;
111(3):
1039 - 1043.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Jin, Y. Tabe, S. Konoplev, Y. Xu, C. E. Leysath, H. Lu, S. Kimura, A. Ohsaka, M.-B. Rios, L. Calvert, et al.
CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells
Mol. Cancer Ther.,
January 1, 2008;
7(1):
48 - 58.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. E. Cortes
Imatinib and Beyond--Therapy of CML in 2008
ASCO Educational Book,
January 1, 2008;
2008(1):
307 - 312.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. M. Kantarjian, F. Giles, N. Gattermann, K. Bhalla, G. Alimena, F. Palandri, G. J. Ossenkoppele, F.-E. Nicolini, S. G. O'Brien, M. Litzow, et al.
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance
Blood,
November 15, 2007;
110(10):
3540 - 3546.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. D. Press, C. Galderisi, R. Yang, C. Rempfer, S. G. Willis, M. J. Mauro, B. J. Druker, and M. W.N. Deininger
A Half-Log Increase in BCR-ABL RNA Predicts a Higher Risk of Relapse in Patients with Chronic Myeloid Leukemia with an Imatinib-Induced Complete Cytogenetic Response
Clin. Cancer Res.,
October 15, 2007;
13(20):
6136 - 6143.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Jabbour, H. M. Kantarjian, L. V. Abruzzo, S. O'Brien, G. Garcia-Manero, S. Verstovsek, J. Shan, M. B. Rios, and J. Cortes
Chromosomal abnormalities in Philadelphia chromosome negative metaphases appearing during imatinib mesylate therapy in patients with newly diagnosed chronic myeloid leukemia in chronic phase
Blood,
October 15, 2007;
110(8):
2991 - 2995.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. M. Goldman
How I treat chronic myeloid leukemia in the imatinib era
Blood,
October 15, 2007;
110(8):
2828 - 2837.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. White, V. Saunders, A. Grigg, C. Arthur, R. Filshie, M. F. Leahy, K. Lynch, L. B. To, and T. Hughes
Measurement of In Vivo BCR-ABL Kinase Inhibition to Monitor Imatinib-Induced Target Blockade and Predict Response in Chronic Myeloid Leukemia
J. Clin. Oncol.,
October 1, 2007;
25(28):
4445 - 4451.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. A. Schiffer
BCR-ABL Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia
N. Engl. J. Med.,
July 19, 2007;
357(3):
258 - 265.
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kantarjian, R. Pasquini, N. Hamerschlak, P. Rousselot, J. Holowiecki, S. Jootar, T. Robak, N. Khoroshko, T. Masszi, A. Skotnicki, et al.
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
Blood,
June 15, 2007;
109(12):
5143 - 5150.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Picard, K. Titier, G. Etienne, E. Teilhet, D. Ducint, M.-A. Bernard, R. Lassalle, G. Marit, J. Reiffers, B. Begaud, et al.
Trough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemia
Blood,
April 15, 2007;
109(8):
3496 - 3499.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Sinai, R. E. Berg, J. M. Haynie, M. J. Egorin, R. L. Ilaria Jr, and J. Forman
Imatinib Mesylate Inhibits Antigen-Specific Memory CD8 T Cell Responses In Vivo
J. Immunol.,
February 15, 2007;
178(4):
2028 - 2037.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. Ma, R. Tseng, M. Gorre, I. Jilani, M. Keating, H. Kantarjian, J. Cortes, S. O'Brien, F. Giles, and M. Albitar
Plasma RNA as an alternative to cells for monitoring molecular response in patients with chronic myeloid leukemia
Haematologica,
February 1, 2007;
92(2):
170 - 175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Branford
Chronic Myeloid Leukemia: Molecular Monitoring in Clinical Practice
Hematology,
January 1, 2007;
2007(1):
376 - 383.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. P. Steensma and R. E. Richard
Myeloproliferative disorders
ASH Self-Assessment Program,
January 1, 2007;
2007(1):
172 - 227.
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. R. Luo, Z. Yang, A. Camuso, R. Smykla, K. McGlinchey, K. Fager, C. Flefleh, S. Castaneda, I. Inigo, D. Kan, et al.
Dasatinib (BMS-354825) Pharmacokinetics and Pharmacodynamic Biomarkers in Animal Models Predict Optimal Clinical Exposure
Clin. Cancer Res.,
December 1, 2006;
12(23):
7180 - 7186.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Baccarani, G. Saglio, J. Goldman, A. Hochhaus, B. Simonsson, F. Appelbaum, J. Apperley, F. Cervantes, J. Cortes, M. Deininger, et al.
Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet
Blood,
September 15, 2006;
108(6):
1809 - 1820.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Tefferi, G. Barosi, R. A. Mesa, F. Cervantes, H. J. Deeg, J. T. Reilly, S. Verstovsek, B. Dupriez, R. T. Silver, O. Odenike, et al.
International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT)
Blood,
September 1, 2006;
108(5):
1497 - 1503.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
H. Kantarjian, F. Giles, L. Wunderle, K. Bhalla, S. O'Brien, B. Wassmann, C. Tanaka, P. Manley, P. Rae, W. Mietlowski, et al.
Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL.
N. Engl. J. Med.,
June 15, 2006;
354(24):
2542 - 2551.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. L. Wang, J. W. Lee, E. Cesarman, D. K. Jin, and B. Csernus
Molecular Monitoring of Chronic Myelogenous Leukemia: Identification of the Most Suitable Internal Control Gene for Real-Time Quantification of BCR-ABL Transcripts
J. Mol. Diagn.,
May 1, 2006;
8(2):
231 - 239.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Koyama, S. Koschmieder, S. Tyagi, I. Portero-Robles, J. Chromic, S. Myloch, H. Nurnberger, T. Rossmanith, W.-K. Hofmann, D. Hoelzer, et al.
Inhibition of phosphotyrosine phosphatase 1B causes resistance in BCR-ABL-positive leukemia cells to the ABL kinase inhibitor STI571.
Clin. Cancer Res.,
April 1, 2006;
12(7 Pt 1):
2025 - 2031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P. Ault, H. Kantarjian, S. O'Brien, S. Faderl, M. Beran, M. B. Rios, C. Koller, F. Giles, M. Keating, M. Talpaz, et al.
Pregnancy Among Patients With Chronic Myeloid Leukemia Treated With Imatinib
J. Clin. Oncol.,
March 1, 2006;
24(7):
1204 - 1208.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. Hughes
ABL Kinase Inhibitor Therapy for CML: Baseline Assessments and Response Monitoring
Hematology,
January 1, 2006;
2006(1):
211 - 218.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Chiaretti, A. Guarini, M. S. De Propris, S. Tavolaro, S. Intoppa, A. Vitale, S. Iacobelli, L. Elia, C. Ariola, J. Ritz, et al.
ZAP-70 expression in acute lymphoblastic leukemia: association with the E2A/PBX1 rearrangement and the pre-B stage of differentiation and prognostic implications
Blood,
January 1, 2006;
107(1):
197 - 204.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Kimura, H. Naito, H. Segawa, J. Kuroda, T. Yuasa, K. Sato, A. Yokota, Y. Kamitsuji, E. Kawata, E. Ashihara, et al.
NS-187, a potent and selective dual Bcr-Abl/Lyn tyrosine kinase inhibitor, is a novel agent for imatinib-resistant leukemia
Blood,
December 1, 2005;
106(12):
3948 - 3954.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Hess, D. Bunjes, W. Siegert, R. Schwerdtfeger, G. Ledderose, B. Wassmann, G. Kobbe, M. Bornhauser, A. Hochhaus, A. J. Ullmann, et al.
Sustained Complete Molecular Remissions After Treatment With Imatinib-Mesylate in Patients With Failure After Allogeneic Stem Cell Transplantation for Chronic Myelogenous Leukemia: Results of a Prospective Phase II Open-Label Multicenter Study
J. Clin. Oncol.,
October 20, 2005;
23(30):
7583 - 7593.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Golemovic, S. Verstovsek, F. Giles, J. Cortes, T. Manshouri, P. W. Manley, J. Mestan, M. Dugan, L. Alland, J. D. Griffin, et al.
AMN107, a Novel Aminopyrimidine Inhibitor of Bcr-Abl, Has In vitro Activity against Imatinib-Resistant Chronic Myeloid Leukemia
Clin. Cancer Res.,
July 1, 2005;
11(13):
4941 - 4947.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. C. Wolff, D. R. Veach, W. P. Tong, W. G. Bornmann, B. Clarkson, and R. L. Ilaria Jr
PD166326, a novel tyrosine kinase inhibitor, has greater antileukemic activity than imatinib mesylate in a murine model of chronic myeloid leukemia
Blood,
May 15, 2005;
105(10):
3995 - 4003.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Cortes, M. Talpaz, S. O'Brien, D. Jones, R. Luthra, J. Shan, F. Giles, S. Faderl, S. Verstovsek, G. Garcia-Manero, et al.
Molecular Responses in Patients with Chronic Myelogenous Leukemia in Chronic Phase Treated with Imatinib Mesylate
Clin. Cancer Res.,
May 1, 2005;
11(9):
3425 - 3432.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. L. Dewar, A. C. Cambareri, A. C. W. Zannettino, B. L. Miller, K. V. Doherty, T. P. Hughes, and A. B. Lyons
Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib
Blood,
April 15, 2005;
105(8):
3127 - 3132.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Quintas-Cardama, H. Kantarjian, M. Talpaz, S. O'Brien, G. Garcia-Manero, S. Verstovsek, M. B. Rios, K. Hayes, A. Glassman, B. N. Bekele, et al.
Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia
Blood,
March 15, 2005;
105(6):
2281 - 2286.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. L. Ilaria Jr.
Pathobiology of Lymphoid and Myeloid Blast Crisis and Management Issues
Hematology,
| |
